RegisterLogin

Modakafusp alfa

CAT: 0804-HY-P99744-01Size: 1 mgDry Ice: YesHazardous: No
CAT#: HY-P99744-01Size: 1 mg
Selected
PRICE
AVAILABILITY
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Modakafusp alfa (TAK-573) is a humanized, anti-CD38 IgG4 monoclonal antibody fused to 2 attenuated IFNα2b molecules, which delivers interferon-alpha to CD38-expressing cells. Modakafusp alfa has direct anti-proliferative activity on multiple myeloma (MM) cancer cells in vitro and induces robust and durable antitumor responses in MM xenograft tumor models. Modakafusp alfa in combination with anti-PD-1 antibodies induces immunomodulation and antitumor responses with good tolerance in mice[1][2][3][4].
CAS Number
[2254522-19-3]
Product Name Alternative
TAK-573
UNSPSC
12352203
Target
CD38
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/modakafusp-alfa.html
Purity
96.22
Solubility
10 mM in DMSO
Smiles
[Modakafuspalfa]
Molecular Weight
(183.48 kDa)
References & Citations
[1]Dan T. Vogl MD, et al. TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma.Blood. 2020, 136 (1), 37-38. |[2]Fatholahi M, et al. TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo[J]. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19 (10) : e116.|[3]Hara T, et al. A murine reactive version of TAK-573 (anti-CD38 attenuated IFNα fusion protein) shows immunomodulatory and antitumor activity, alone and in combination with standard-of-care agents, in IFNa-insensitive, immunocompetent murine multiple myeloma tumor models[J]. Cancer Research, 2020, 80 (16_Supplement) : 5546-5546.|[4]Bruins W S C, et al. Modakafusp alfa (TAK-573), a novel CD38-targeting attenuated interferon-alpha immunocytokine, kills MM cells via NK cell activation[J]. Blood, 2022, 140 (Supplement 1) : 4236-4237.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2

Related Products

CatalogName
HY-171612Follitropin alfa, Lutropin alfa (2:1)
HY-P99479-01Bifikafusp alfa
HY-P990966Redalsomatropin alfa
HY-P99933Eftilagimod alfa
HY-P990987Efdoralprin alfa
HY-P990974Bezeotermin alfa
HY-P99917-01Eflepedocokin alfa
HY-P99879-01Efbemalenograstim alfa
HY-P99902-01Simlukafusp alfa
HY-P99934-01Eftozanermin alfa

Alternative Products

CatalogName
T77091-01Modakafusp alfa
abx831657-01Modakafusp Alfa
MBS5819012Modakafusp alfa
HB691056-01Research Grade Modakafusp alfa
DHD80805Research Grade Modakafusp alfa
MBS1563668-01Research Grade Modakafusp alfa
E55B0946Modakafusp alfa (Reference antibody)
A134916Modakafusp alfa Biosimilar (Monoclonal, IgG4-kappa)
592015Modakafusp
MBS1563127-01Modakafusp

Popular Products